Table 1.
Zebrafish models of human AML and MDS.
| Human mutated factors | Correlating human disease | Zebrafish manipulation | Reference |
|---|---|---|---|
| AML-ETO t(8;21)(q22;q22) | AML | Transgenic expression of human AML-ETO fusion | (50, 133) |
| TEL-JAK2 t(9;12)(p24;p13) | AML | Transgenic expression of human TEL2-JAK2 fusions | (58, 59) |
| FLT3-ITD, FLT3 TKD | AML | Transgenic expression of human FLT3-ITD or FLT3-TKD | (52, 64, 65) |
| NPM1c | AML | Knockdown of zebrafish npm1 homolog; transgenic expression of human NPM1c | (67, 69) |
| IDH1/2 | AML | Knockdown of zebrafish idh1 and idh2 homologs; transgenic expression of human IDH1 point mutant | (72) |
| MYST3-NCOA2 inv(8)(p11;q13) | AML | Transgenic expression of human MYST3-NCOA2 fusion under the spi1/pu.1 promoter | (74) |
| NUP98-HOXA9 t(7;11)(p15;15) | AML | Transgenic expression of human NUP98-HOXA9 fusion under the spi1/pu.1 promoter | (78, 79) |
| SF3B1 | MDS | sf3b1hi3394a mutant | (100) |
| U2AF1 | MDS | u2af1hi199 mutant | (107) |
| PRPF8 | MDS | prpf8gl1/cephalophonusgl1 mutant | (111) |
| TET2/3 | MDS | tet2zdf20, tet2mk17, and tet3k18 mutants | (118, 119) |
| RPS14 | Ribosomopathy (5q− MDS) | rps14zf624 mutant | (126) |
| RPS19 | Ribosomopathy (DBA) | rps19zf556 mutant | (129, 134) |
| HSPA9B | Ribosomopathy (5q− MDS) | hspa9bunspecified/crimsonlessunspecified mutant | (123) |
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ETO, eight twenty one; JAK2, Janus kinase 2; FLT3, FMS-like tyrosine kinase 3; ITD, internal tandem duplication; TKD, tyrosine kinase domain; NPM1, nucleophosmin 1; IDH1/2, isocitrate dehydrogenase 1 and 2; NCOA2, nuclear co-activator 2; NUP98, nuclear pore complex protein 98; HOXA9, homeobox protein A9; SF3B1, splicing factor 3B, subunit 1; U2AF1, U2 small auxiliary factor 1; PRPF8, pre-mRNA processing factor 8; TET2/3, Ten-eleven translocation; HSPA9B, heat shock protein family A member 9B; DBA, Diamond–Blackfan anemia.